Antituberculosis activity of the molecular libraries screening center network library

Tuberculosis

Volumn 89, Issue 5, 2009, Pages 354-363

  Maddry, Joseph A ^a   Ananthan, Subramaniam ^a   Goldman, Robert C ^b   Hobrath, Judith V ^a   Kwong, Cecil D ^a   Maddox, Clinton ^a   Rasmussen, Lynn ^a   Reynolds, Robert C ^a   Secrist III, John A ^a   Sosa, Melinda I ^a   White, E Lucile ^a   Zhang, Wei ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Respiratory Diseases Branch   (United States)

Author keywords

Antitubercular; High throughput screening; Medicinal chemistry analysis; MLSCN; Small molecule chemical library; TAACF; Tuberculosis

Indexed keywords

1,2,4 THIADIAZOLE DERIVATIVE; 1,3,4 OXADIAZOLE DERIVATIVE; 2 CARBOXAMIDO 1,3,4 OXADIAZOLE DERIVATIVE; 3 (TRIFLUOROMETHYL) 4 (PIPERAZINYLMETHYL)ANILINE; 3 PHENYLPYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; 4 THIAZOLIDINONE DERIVATIVE; 4(5) PHENYLACETYLIMIDAZOLE 5(4) CARBOXAMIDE DERIVATIVE; 5 NITROFURAN 2 CARBOXAMIDE DERIVATIVE; AMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); IMIDAZO[1,2 A]PYRIDINE 3 AMINES; OXADIAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TETRAHYDROPYRAZOLOL[1,5 A]PYRIMIDINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; MOLECULAR LIBRARY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; CLUSTER ANALYSIS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH; SMALL MOLECULE LIBRARIES; TUBERCULOSIS;

EID: 70449108128     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2009.07.006     Document Type: Article

References (34)

1. WHO. World Health Organization. Global Tuberculosis Control 2008. Surveillance, Planning, Financing (2008), WHO
2. Espinal M.A. The global situation of MDR-TB. Tuberculosis (Edinb) 83 (2003) 44-51
3. Mondal R., and Jain A. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerging Infect Dis 13 (2007) 1429-1431
4. Cohen T., and Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10 (2004) 1117-1121
5. http://www.who.int/entity/tb/challenges/xdr/xdr_map_june08.pdf
6. Goldman R.C., Laughon B.E., Reynolds R.C., Secrist III J.A., Maddry J.A., Guie M.-A., et al. Programs to facilitate tuberculosis drug discovery: the Tuberculosis Antimicrobial Acquisition and Coordinating Facility. Infect Disord-Drug Targets 7 (2007) 92-104
7. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, et-al,. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis, 2009; in press doi:10.1016/j.tube.2009.05.008.
8. http://pubchem.ncbi.nlm.nih.gov/
9. Takahashi H., Hayakawa I., and Akimoto T. The history of the development and changes of quinolone antibacterial agents. Yakushigaku Zasshi 38 (2003) 161-179
10. Mduli K., and Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord-Drug Targets 7 (2007) 159-168
11. Reddy G.V., Kanth S.R., Maitraie D., Narsaiah B., Rao P.S., Kishore K.H., et al. Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides. Eur J Med Chem 44 (2009) 1570-1578
12. Morgan J., Haritakul R., and Keller P.A. Anilinopyrimidines as novel antituberculosis agents. Bioorg Med Chem Lett 13 (2003) 1755-1757
13. Agarwal A., Srivastava K., Puri S.K., Sinha S., and Chauhan P.M. A small library of trisubstituted pyrimidines as antimalarial and antitubercular agents. Bioorg Med Chem Lett 15 (2005) 5218-5221
14. Raghavendra N.M., Thampi P., Gurubasavarajaswamy P.M., and Sriram D. Synthesis, antitubercular and anticancer activities of substituted furyl-quinazolin-3(4 H)-ones. Arch Pharm 340 (2007) 635-641
15. Nanda A.K., Ganguli S., and Chakraborty R. Antibacterial activity of some 3-(arylideneamino)-2-phenylquinazoline-4(3H)-ones: synthesis and preliminary QSAR studies. Molecules 12 (2007) 2413-2426
16. Raghavendra N.M., Thampi P., Gurubasavarajaswamy P.M., and Sriram D. Synthesis and antimicrobial activities of some novel substituted 2-imidazolyl- N-(4-oxo-quinazolin-3(4 H)-yl)-acetamides. Chem Pharm Bull 55 (2007) 1615-1619
17. Alagarsamy V., Rajasolomon V., Meena R., and Ramseshu K.V. Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-butyl-3-substituted quinazolin-4-(3 H)-ones. Biol Pharm Bull 28 (2005) 1091-1094
18. Nasr M.N., Gineinah M.M., and El-Bendary E.R. Synthesis and in vitro antibacterial evaluation of novel imidazo[2′,1′:5,1]-1,2,4,-triazolo[4,3-c]-quinazoline derivatives of 5-thioxo-1,2,4-triazole, 4-oxothiazolidine, and their open-chain counterparts. Arch Pharm 336 (2003) 560-566
19. Bedi P.M.S., Kumar V., and Mahajan M.P. Synthesis and biological activity of novel antibacterial quinazolines. Bioorg Med Chem Lett 14 (2004) 5211-5213
20. De La Fuente R., Sonawane N.D., Arumainayagam D., and Verkman A.S. Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening. Br J Pharmacol 149 (2006) 551-559
21. Kumar S., Jaller D., Patel B., LaLonde J.M., DuHadaway J.B., Malachowski W.P., et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 51 (2008) 4968-4977
22. Yang J., Gharagozloo P., Yao J., Ilyin V.I., Carter R.B., Nguyen P., et al. 3-(4-Phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem 47 (2004) 1546-1552
23. Mamolo M.G., Zampieri D., Vio L., Fermeglia M., Ferrone M., Pricl S., et al. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3 H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. Bioorg Med Chem 13 (2005) 3797-3809
24. Foks H., Ancechowska-Ksepko D., Janowiec M., Zwolska Z., and Augustynowicz- Kopec E. Synthesis and tuberculostatic activity of some (4-phenylpiperazin-1-ylmethyl)-1,3,4-oxadiazole and (4-phenylpiperazin-1-ylmethyl)-1,2,4-triazole derivatives. Acta Pol Pharm 61 (2004) 473-476
25. Pancechowsak-Ksepko D., Foks H., Janowiec M., and Zwolska-Kwiek Z. Synthesis and tuberculostatic activity of reaction products 5-(2-,3- and 4-pyridil)-1,3,4-oxadiazol-2-thione with amines. Acta Pol Pharm 50 (1993) 259-267
26. Yar M.S., Siddiqui A.A., and Ali M.A. Synthesis and anti tuberculostatic activity of novel 1,3,4-oxadiazole derivatives. J Chin Chem Soc 54 (2007) 5-8
27. Joshi S.D., Vagdevi H.M., Vaidya V.P., and Gadaginamath G.S. Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole, and pyrrole ring systems: a novel class of potential antibacterial and antitubercular agents. Eur J Med Chem 43 (2008) 1989-1996
28. Yousif N.M., Mandour A.H., and Omar M.T. Synthesis and reactions of some 1,2,4-thiadiazole derivatives for biological evaluation. Egypt Chem 32 (1991) 607-614 [actual volume date 1989]
29. Finn J., Stidham M., Hilgers M., and Kedar G.C. Identification of novel inhibitors of methionyl-tRNA synthetase (MetRS) by virtual screening. Bioorg Med Chem Lett 18 (2008) 3932-3937
30. Litvinchuk M.D. Pharmacological assays of new tuberculostatic drugs. Farmakoli Toxicol 26 (1963) 725-729
31. Fujikawa F., Hirai K., Hirayama T., Yoshikawa T., Nakagawa T., Naito M., et al. Chemotherapeutics for Mycobacterium tuberculosis. XXII.: synthesis and antibacterial activity on Mycobacterium tuberculosis of N2-(2-pyridyl)-3-(p-ethoxyphenyl)pseudothiohydantoin and N2-(2-benzothiazolyl)-3-allylpseudothiohydantoin derivatives. Yakugaku Zasshi 89 (1969) 1099-1103
32. Zubenko V.G., Ladnaya L.Y., Turkevich N.M., and Tatchin-kapustyak S.M. Synthesis and tuberculostatic activity of azolidines. Farm Zh 29 (1974) 78-82
33. Danila G., and Radu C. Derivatives of 2-thioxo-3-isonicotinylaminothiazolid-4-one with tuberculostatic activity. Rev Med-Chir 82 (1978) 127-130
34. Tangallapally R.P., Yendapally R., Daniels A.J., and Lee R.E. Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. Curr Top Med Chem 7 (2007) 509-526